Skip to main content

Created with Sketch.

NewSTEPs
  • Log in
  • Sign up

Main Menu

  • About NewSTEPs
    • Screening Successes
    • Continuous Quality Improvement
    • Request Site Review
    • FAQs
  • Newborn Screening Disorders
  • Resource Library
    • Toolkits
    • Webinars & Events
  • Data Center
    • NBS Cases
    • Quality Indicators
    • State Profiles
    • Dashboards and Reports
    • Request Data
  • Manage Data
    • User Management
    • Submit Confirmed Case Data
    • Submit Quality Indicator Data
    • Submit State Profile Data
    • Data Dictionary
  • Log in
  • Sign up
  • NewSTEPs
  • Resource Library
  • Newborn Screening (NBS) + Enzyme Replacement Therapy= Improved Lysosomal Storage Disorder (LSD): Outcomes in Infantile-Onset Pompe Disease

Newborn Screening (NBS) + Enzyme Replacement Therapy= Improved Lysosomal Storage Disorder (LSD): Outcomes in Infantile-Onset Pompe Disease

Date: January 2015

This article discusses the benefits of newborn screening (NBS) early detection and early intervention therapies for patients with Pompe and other lysosomal storage disorders (LSDs).

Newborn Screening + Enzyme Replacement Therapy = Improved Lysosomal Storage Disorder: Outcomes in Infantile-Onset Pompe Disease

Tags

  • Publications

Share

Outdated Browser

This website is not compliant with Internet Explorer. Please continue your experiense using Microsoft Edge, or another up-to-date browser.

This resource, a program of APHL, was developed by funding from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U22MC24078 for $2,300,000.

Follow

newsteps@aphl.org
© Copyright 2023 Association of Public Health Laboratories